Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V- HeFT III

Circulation

Volumn 96, Issue 3, 1997, Pages 856-863

  Cohn, Jay N ^a   Ziesche, Susan ^a   Smith, Raphael ^a   Anand, Inder ^a   Dunkman, W Bruce ^a   Loeb, Henry ^a   Cintron, Guillermo ^a   Boden, William ^a   Baruch, Lawrence ^a   Rochin, Peter ^a   Loss, Larrye ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Atrial natriuretic factor; Calcium channels; Heart failure; Morbidity; Norepinephrine

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATRIAL NATRIURETIC FACTOR; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; GLYCERYL TRINITRATE; NITRATE; VASODILATOR AGENT;

ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; EDEMA; EXERCISE TOLERANCE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL DRUG ADMINISTRATION; TREADMILL EXERCISE;

EID: 0030835847     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.3.856     Document Type: Article

References (34)

1. Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure. N Engl J Med. 1977:297:27-31, 254-258.
2. Ziesche S, Cobb FR, Cohn JN, Johnson G, Tristani F, for the V-HeFT VA Cooperative Studies Group. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure: results from V-HeFT I and V-HeFT II. Circulation. 1993;87(suppl VI):VI-56-VI-64.
3. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med. 1986;314: 1547-1552.
4. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316: 1429-1435.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
6. Cohn JN, Johnson G. Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
7. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, Luu M, Hamilton MA, Moriguchi JD, Tillisch JH, Walden JA, Albanese E. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C Trial. J Am Coll Cardiol. 1992;19: 842-850.
8. Packer M. Calcium channel blockers in chronic heart failure: the risks of ''physiologically rational' therapy. Circulation. 1990;82: 2254-2257.
9. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. The Adverse Experience Committee and the Multicenter Diltiazem Post-Infarction Research Group: diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83:52-60.
10. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy to isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954-1961.
11. Agostini PG, DeCesare N, Doria E, Polese A, Tamborini G, Guazzi MD. Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy. Br Heart J. 1986;55:391-399.
12. Culling W, Ruttley MSM, Sheridan DJ. Acute hemodynamic effects of felodipine during β-blockade in patients with coronary artery disease. Br Heart J. 1984;52:431-434.
13. Cheng C-P, Igarashi Y, Pettersson K, Little WC. Effect of felodipine on left ventricular performance in conscious dogs: assessment by left ventricular pressure-volume analysis. J Pharm Exp Ther. 1991;257:163-169.
14. Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin M, Packer M, Murphy BE, Neuberg GW, Steingart RM, Levine TB, deHaan H, for the FACET Investigators. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Circulation. 1993;88: 492-501.
15. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M, for the PROFILE Investigators. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation. 1993;88(suppl I):I-301. Abstract.
16. Boden WE, Ziesche S, Carson PE, Conrad CH, Syat D, Cohn JN, for the V-HeFT III Investigators. Rationale and design of the third Vasodilator-Heart Failure Trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. Am J Cardiol. 1996,77: 1078-1982.
17. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK, for the PROVED Investigative Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol. 1993;22(4):955-962.
18. Packer M, Gheorghiade M, Young JB, Constantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK, for the RADIANCE Study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med. 1993;329:1-7.
19. Cohn JN. Drug therapy: the management of chronic heart failure. N Engl J Med. 1996:335;490-498.
20. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R, for the V-HeFT VA Cooperative Studies Group. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 1993; 87(suppl VI):VI-5-VI-16.
21. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN, for the V-HeFT VA Cooperative Studies Group. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation. 1993;87(suppl VI):VI-17-VI-23.
22. 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation. 1994;90:3034-3046.
23. McDonald KM, Francis GS, Matthews JH, Hunter D, Cohn JN. Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog. J Am Coll Cardiol. 1993;21:514-522.
24. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, Goldstein S. Effects of long term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation. 1994;89:2852-2859.
25. McDonald KM, Rector T, Carlyle PF, Francis GS, Cohn JN. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol. 1994;24: 1762-1768.
26. Dzau VJ. The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. Curr Opin Nephrol Hypertens. 1993;2:27-32.
27. Cerasola G, Cottone S, Nordi E, Fulantelli MA, Carone MB, D'Ignoto G. Reversal of cardiac hypertrophy and left ventricular function with the calcium antagonist felodipine in hypertensive patients. J Hum Hypertens. 1990;4:703-708.
28. Konstam MA, Dracup K, Baker DW, Bottorff MB, Brooks NH, Dcey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, Jones RH, Luchi RJ, Massie BM, Pitt B, Rose EA, Rubin LJ, Wright RF, Hadorn DC. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. J Card Failure. 1995;1:183-187.
29. ACC/AHA Task Force Report. Guidelines for the evaluation and management of heart failure. Circulation. 1995;92:2764-2784.
30. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, Shaknovich A, Pondolfino K, Clark C, Camargo MJF, Scarborough RM, Lewicki-JA. Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal hormonal and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78: 1362-1374.
31. Littler WA, Sheridan DJ, for the UK Study Group. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Br Heart J. 1995;73:428-433.
32. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107-1114.
33. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation. 1993;87(suppl VI):VI-40-VI-48.
34. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274: 620-625.